E

New developments on the lymphoma horizon

Key learnings and highlights from the recent AACR DLBCL specialist meeting

October 5, 2021
E

When things fall apart

One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…

September 29, 2021
E

Storm Clouds or Sunny Skies? What’s on the horizon for Early Stage IO Development Data at ESMO21

A hard look at some IO agents in early development at ESMO21

September 18, 2021
E

WCLC21 Preview of key data to watch out for

What's hot at WCLC21?

August 19, 2021
E

A novel target to explore in prostate cancer

Is it a marker or a target? Actually, what is the target - and why does it matter?

August 5, 2021
E

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020
E

Gritting it out

What are Gritstone up to behind the scenes and where are they headed in the near-term?

July 20, 2021
E

New developments on the T cell engager front

Update on the T cell engager niche with an emerging agent of interest

July 8, 2021
E

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021
E

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021
E

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021
E

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021
E

AACR21 Preview 8 – The growing bispecific niche

A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting

April 8, 2021
E

Novel combination strategies to enhance KRAS inhibitors

Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!

March 16, 2021
E

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021
E

A look at the exon 20 landscape in lung cancer

A look at the exon 20 insertion landscape - all to play for!

February 4, 2021
E

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021
E

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021
E

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021
E

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021
E

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021
E

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021
E

A critical review of bispecific antibodies at ASH20

What caught our attention on novel bispecific antibodies at ASH20?

December 7, 2020
E

ASH20 Preview of progress with bispecific antibodies

Updated look at the bispecific landscape in early clinical development

November 9, 2020
E

Potential new targets and biomarkers for immunotherapy

How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development

October 20, 2020
E

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
E

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020
E

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Five IO areas in early stage development to watch out for at ESMO20

September 15, 2020
E

ESMO20 Preview 2 – New Targets, New Opportunities

Can we predict the future cancer drug combinations from emerging new targets?

September 10, 2020
E

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020
E

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020
E

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020
E

Looking through the window at some novel new product development concepts in oncology

A look at some novel and promising approaches in early oncology new product development

June 24, 2020
E

Who is winning the CD20xCD3 Bispecific Race to Market?

An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.

June 15, 2020
E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020
E

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019
E

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019
E

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019
E
National Harbor Maryland

Key Highlights from Day 1 at SITC19

If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far

November 8, 2019
E

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019
E

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019
E
AMG 596 EGFRvIII BiTE

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019
E

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019
E

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019
E

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019
E

Key highlights on lymphomas from iCML

Round-up and analysis of key lymphoma data at iCML 2019

June 20, 2019
E

Insights from CIMT in Mainz Part 2

Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.

May 23, 2019
E

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019
E

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019
E

Defense is the Best Attack – Part 1

Update on T cell bispecifics and other key topics in early stage IO development

March 12, 2019
E

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019
E

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019
E

Insights from the ASCO GI19 conference

What to watch out for at the ASCO GI19 conference in San Francisco

January 17, 2019
E

A tale of two cities – a look at two small immunotherapy biotechs

Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy

January 14, 2019
E

The challenges of bispecifics

FDA slaps a partial clinical hold for unwanted side effects, now what?

December 11, 2018
E

ASH18 Highlights from Day 3

Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!

December 3, 2018
E

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018
E

ASH18 Preview 3 – BCMA

From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?

November 26, 2018
E

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018
E

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018
E

Preview of CICON18 – Part 1

Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies

September 20, 2018
E

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018
E

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018
E

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018
E

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018
E

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018
E

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018
E

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017
E

AACR18 Day 2 Highlights

A look at the Class of 2018 new products in development - a hit or miss?

April 16, 2018
E

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017
E

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017
E

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017
E
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017
E

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016
E

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016
E

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016
E

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015
E

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017
E

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015